This is the second article in a series of two articles addressing management of seizures. A link to the first article is provided below:
ANTI-EPILEPTIC DRUG (AED) CHOICE
A major determinant of AED choice is the type of seizure. Narrow spectrum AEDs are effective in controlling either partial OR generalized type seizures, while broad spectrum AEDs can treat both partial AND generalized seizure disorders.
Narrow spectrum AEDs that treat partial seizure types include carbamazepine, oxcarbazepine, gabapentin, pregabalin, tiagabine, vigabatrin, and lacosamide.
Narrow spectrum AEDs that treat generalized seizure types include rufinamide, which is especially useful in atonic seizures associated with Lennox-Gestaut syndrome, and ethosuximide, which is helpful for absence seizures.
Broad-spectrum agents include levetiracetam, lamotrigine, phenytoin, topiramate, felbamate, zonisamide, valproic acid, and phenobarbital. When the clinician is not sure as to the seizure type involved, a broad spectrum AED should be chosen.
Bone density monitoring, calcium and vitamin D supplementation, and exercise should be considered for all patients on chronic AED therapy.
Click HERE to run the Evaluation of Seizure care pathway interactively. Or, consider signing up for a FREE trial of INFERA to run over 90 care pathways interactively and get quick answers to your management questions:
AEDs in Specific Patient Populations
In some circumstances, specific patient characteristics and conditions can help guide AED choice.
Renally cleared AEDs include gabapentin, topiramate, zonisamide, lacosamide, levetiracetam and pregabalin. The doses of these drugs should be adjusted in patients with renal impairment.
Medications such as valproate, felbamate, phenytoin and carbamazepine can cause hepatic toxicity and generally should be avoided in patients with liver disease. AEDs metabolized by the liver include carbamazepine, lamotrigine, phenytoin, phenobarbital, and oxcarbazepine.
If a decision is made to start anti-epileptic drug therapy, consider using valproate, gabapentin, or topiramate in patients with a history of migraine headaches since these agents are effective in migraine prevention.
Women of childbearing age
Folic acid 4mg daily should be administered for one to three months before conception in patients taking valproate or carbamazepine. Women taking other AEDs should receive a lower dose of folic acid at 0.4 to 0.8 mg daily.
Enzyme-inducing AEDs (carbamazepine, eslicarbazepine, felbamate, lamotrigine, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, Rufinamide, Topiramate, Valproate, Vigabatrin) can increase the failure rate of contraceptives such as the combined hormonal pill, patch or ring contraception. Consider recommending alternative forms of contraception if these AEDs are used. Conversely, combined estrogen-progesterone contraceptives can specifically induce the metabolism of lamotrigine, and higher doses of lamotrigine may be required in patients taking these medications.
Pregnancy: No AED has been shown to be definitively safe in pregnancy; however, valproate has a significant association with fetal malformations and should be avoided in pregnancy and women at risk for pregnancy.
If a decision is made to start anti-epileptic drug therapy, consider using an AED with mood-stabilizing effects in patients with a history of mental disorders. Such AEDs include valproate, lamotrigine, carbamazepine, and oxcarbazepine.
The clinician should also be aware that certain AEDs can worsen psychiatric disorders. For example, medications such as phenobarbital, tiagabine, vigabatrin, and topiramate can worsen depressed mood, while levetiracetam, topiramate, vigabatrin, zonisamide, ethosuximide and perampanel can produce psychosis. Also, AEDs as a class, in general, are associated with an increased risk of suicide and all patients on these medications should be monitored for mood changes and suicidal ideation.
Osteoporosis or osteopenia
Bone density monitoring, calcium and vitamin D supplementation, and exercise should be considered for all patients on chronic AED therapy. Phenytoin specifically has the strongest association with osteoporosis and should be avoided in patients at risk for bone loss.
Valproate should be avoided in patients with diabetes due to its strong association with weight gain and insulin resistance. Other AEDs associated with weight gain include carbamazepine, vigabatrin, gabapentin and pregabalin. AEDs effective in diabetic neuropathy include gabapentin and pregabalin.
Carbamazepine, phenytoin, ethosuximide and valproate are associated with neutropenia and agranulocytosis. Thrombocytopenia has been related to carbamazepine, valproate and phenytoin. Avoid using these AEDs in patients with hematological disorders.
Management of seizures is complex. We have developed a comprehensive algorithm for the treatment of provoked and unprovoked seizures that can be accessed through Infera, our innovative Clinical Decision Support application. The information is evidence based and peer reviewed by board certified neurologists.
Click here to try Infera for free for 30 days.
- Krumholz, S. Wiebe, G. Gronseth et al. Practice Parameter: Evaluating an apparent unprovoked first seizure in adults (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2007; 69; 1996-2007
Adams S.M., Knowles P.D. Evaluation of a First Seizure. Fam Physician 2007; 75: 1342-1348.
Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure 2006; 15:156.
Allan Krumholz, Samuel Wiebe, Gary S. Gronseth, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2015; 84; 1705-1713
Alvarez-Sabín J, Montaner J, PadróL, Molina CA, Rovira R, Codina A, Quintana M. Gabapentin in late-onset poststroke seizures. Neurology. 2002;59(12):1991.
American College of Obstetricians and Gynecologists (ACOG). Neural tube defects. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2003 Jul. 11 p. (ACOG practice bulletin; no. 44).
Ashish K, Strbian D, Sundararajan, S. Early onset seizures in stroke. Stroke. 2014; 45: e249-e251.
Bazil CW. Antiepileptic drugs in the 21st century. CNS Spectr 2001; 6:756.
Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291:965.
Brodtkorb E, Mula M. Optimizing therapy of seizures in adult patients with psychiatric comorbidity. Neurology 2006; 67:S39.
Chang BS, Lowenstein DH. Practice parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 60: 10-16.
Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007; 48:484.
Collins N, Maher J, Cole M, et al. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 1991; 78:113.
Contin M, Albani F, Ambrosetto G, et al. Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. Epilepsia 2006; 47:1573.
Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20:519.
Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767.
Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992; 42:149.
Fields MC, Labovitz DL, French, JA. Hospital-Onset Seizures An Inpatient Study. JAMA Neurol. 2013; 70(3): 360-364.
Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31:1448.
French JA, Pedley TA. Clinical practice. Initial management of epilepsy. N Engl J Med 2008; 359:166.
French, JA, Gazzola Diabetes mellitus. Antiepileptic Drug Treatment: New Drugs and New Strategies. Continuum 2013; 19 (3): 643-655.
García-Morales I, de la Peña Mayor P, Kanner AM. Psychiatric comorbidities in epilepsy: identification and treatment. Neurologist 2008; 14:S15.
Gilad R, Sadeh M, Rapoport A, Dabby R, Boaz M, Lampl Y. Monotherapy of lamotrigine versus carbamazepine in patients with poststroke seizure. Clin Neuropharmacol. 2007;30(4):189.
Haltiner AM, Temkin NR, Sureyya SD. Risk of seizure recurrence after the first late posttraumatic seizure. Arch Phys Med Rehabil 1997; 78:835-40.
Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 2006; 47:1447.
Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update: management issues for women with epilepsy–focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73:142.
Hauser AW, Rich SS, Ju R.-J. Lee, Annegeers JF, Anderson EV. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998; 338: 429-434.
Herzog AG, Blum AS, Farina EL, et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 2009; 72:911.
Israni RK, Kasbekar N, Haynes K, Berns JS. Use of antiepileptic drugs in patients with kidney disease. Semin Dial 2006; 19:408.
Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011; 52:2133.
Labiner DM, Ettinger AB, Fakhoury TA, et al. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia 2009; 50:434.
Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006; 67:S28.
Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013; :CD010611.
M.J. Glantz, B.F. Cole, P.A. Forsyth, et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54; 1886-1893
Maschio M, Dinapoli L, Gomellini S, Ferraresi V, Sperati F, Vidiri A, Muti P, Jandolo B. Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. J Neurooncol. 2010;98(1):109.
Mikati MA, Dib L, Yamout B, et al. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology 2006; 67:2005.
Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014; :CD007938.
Mula M, Hesdorffer DC, Trimble M, Sander JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia 2009; 50:1072.
O’Brien MD, Guillebaud J. Contraception for women with epilepsy. Epilepsia 2006; 47:1419.
Pack A. Effects of Treatment on Endocrine Function in Patients with Epilepsy. Curr Treat Options Neurol 2005; 7:273.
Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005; 57:252.
Pack AM, Morrell MJ, Randall A, et al. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008; 70:1586.
Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010; 182:E269.
Rahman A, Mican LM, Fischer C, Campbell AH. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother 2009; 43:822.
Reese JA, Li X, Hauben M, et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood 2010; 116:2127.
Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005; 46:1414.
Rosati A, Buttolo L, Stefini R, Todeschini A, Cenzato M, Padovani A. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol. 2010;67(3):343.
Rossetti AO, Jeckelmann S, Novy J, Roth P, Weller M, Stupp R. Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro Oncol. 2014 Apr;16(4):584-8. Epub 2013 Dec 4.
Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Lee JW, Kesari S. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. J Neurosurg. 2013;118(6):1183.
Shamliyan TA, Choi JY, Ramakrishnan R, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med 2013; 28:1225.
Sherk HH, Cruz M, Stambaugh J. Vitamin D prophylaxis and the lowered incidence of fractures in anticonvulsant rickets and osteomalacia. Clin Orthop Relat Res 1977; :251.
Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61:490.
Steinhoff BJ. Optimizing therapy of seizures in patients with endocrine disorders. Neurology 2006; 67:S23.
Usery JB, Michael LM 2nd, Sills AK, Finch CK. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol. 2010;99(2):251.
Wegner I, Edelbroek PM, Bulk S, Lindhout D. Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. Neurology 2009; 73:1388.
Zupanc ML. Antiepileptic drugs and hormonal contraceptives in adolescent women with epilepsy. Neurology 2006; 66:S37.